Arnaud Gregoire*
We combined participant-level data from 524 patients across twenty-two eligible clinical trials that met our inclusion criteria. The type and source of the infused cells had a significant impact on the outcome. 58.9 percent of T1DM patients who received CD34+ hematopoietic stem cell (HSC) infusions became insulin-independent for a mean of 16 months, whereas patients who received umbilical cord blood (UCB) consistently failed. When compared to bone marrow mesenchymal stem cells (BM-MSCs), infusion of umbilical cord mesenchymal stem cells (UC-MSCs) significantly improved T1DM outcomes (P 0.0001 and P=0.1557). Early stem cell therapy administration was more effective than later intervention (relative risk=2.0, P=0.0008) after DM diagnosis. Unfriendly impacts were seen in just 21.72% of both T1DM and T2DM foundational microorganism beneficiaries with no detailed mortality. Diabetes ketoacidosis was identified in 79.5% of the poor responders.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 